Allogeneic haematopoietic stem cell transplantation for relapsed/refractory acute leukaemia – a single-centre experience

Ref ID: 18571

Author:

T.D. Tan, M.C. Wu, J.L.W. Chiou

Author address:

Koo Foundation Sun Yat-Sen Cancer Center (Taipei, TW)

Full conference title:

Annual Meeting of the EBMT, 36th

Abstract:

Purpose: For relapsed or refractory acute leukemia, the curative
treatment of choice is allogeneic hematopoietic stem cell transplantation if patients could tolerate transplant therapy feasibly and
an HLA mutched donor available. If not, patients could just go into S95
clinical trial with novel agents or supportive care. However, the
transplant related morbidity and mortality is higher and the eventfree and overall survival are worse than patient in remission.
Materials and methods: We evaluated our 20 patients who
are relapsed or refractory acute leukemia after the treatment
of remission induction and high dose Ara-C and mitoxantrone
(HAM) chemotherapy or prior autologous or allogeneic stem
cell transplantation between February 2004 and October 2009.
All these patients underwent allogeneic hematopoietic stem cell
transplantation with matched related or unrelated donor.
Results: Twenty patients included 11 male and 9 female with
median age 40.8 years old (range 21~60). Diagnosis included
AML (N = 15, including 4 therapy-related), ALL (N = 3), and
CML-BP (n = 2). There were 16 patients (80%) having undergone high dose Ara-C plus mitoxantrone (HAM) chemotherapy. Four patients (20%) had had prior transplant treatment.
Four patients were graft failure and died in 1 month. For the
other 15 evaluable patients, 5 patients were leukemia free but
one of them died of pulmonary invasive aspergillosis. Posttransplant relapse occurred in 10 patients (66.7%), but in 7
patients underwent salvage chemotherapy alone (n = 1) or salvage chemotherapy plus donor leukocyte infusion (n = 6) with
5 leukemia-free achieved. In general, 9 patients died of leukemia, 3 patients died of infection, and 1 patients died of unknown
cause of hepatic failure. Three year event-free survival is 22%
and overall survival 23%.
Conclusions: As expected, the relapse rate is very high and
most patients died of leukemia itself but some patients still
could be salvaged by re-chemotherapy plus CD34-riched
donor leukocyte infusion or second transplantation. Therefore,
the plan of programmed prophylactic donor lymphocyte infusion is mandatory.

Abstract Number: P430

Conference Year: 2010

Link to conference website: NULL

New link: NULL

Conference abstracts, posters & presentations

Showing 10 posts of 17325 posts found.

  • Title

    Author

    Year

    Number

    Poster